MENU

Can Tempus AI (TEM) Stock Reach $92?

A.I.Advisor
published price charts
A.I.Advisor
Nov 03, 2026

Can Tempus AI (TEM) Stock Reach $92?

Key Takeaways

  • The central $92 stock price target is the arithmetic mean of six verified analyst targets that sit above the current share price; the overall mean of the 14 recent targets reviewed is closer to $80.
  • Tempus AI, Inc. (TEM) closed near $78.48, meaning the $92 target implies roughly 17% upside from recent levels.
  • Current analyst targets span a wide range of roughly $67 to $100, reflecting genuine disagreement about the pace of profitability and valuation.
  • The strongest support comes from accelerating oncology-testing volumes, rising data-and-applications revenue, and expanding pharmaceutical partnerships.
  • The biggest risks are an unprofitable GAAP bottom line, a high price-to-book valuation, and execution risk around the pending Personalis acquisition.
  • For more detail on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
  • Discover Trending AI Robots to see how artificial intelligence is being applied to stock and ETF trading signals.

Analyst Price Targets and Consensus View

Tempus AI, Inc. (TEM) is a healthcare-technology company that applies artificial intelligence and machine learning to diagnostics and drug research. Its shares are followed by a broad group of Wall Street firms, and the spread of opinions is unusually wide for a company of its size.

Fourteen recent analyst price targets were reviewed, spanning roughly $67 to $100. The overall arithmetic mean of those targets is approximately $80. Because that average sits only slightly above the prevailing share price, the central target used here reflects the six targets that are above the current price — BTIG at $100, Canaccord Genuity at $95, Cantor Fitzgerald, Baird, and Guggenheim at $92 each, and Raymond James at $80 — whose mean rounds to $92. This is a calculation, not an independently published consensus.

Post-earnings revisions illustrate the divide. BTIG's Mark Massaro kept a Buy and lifted the target from $80 to $100, while Cantor Fitzgerald (Overweight) and Baird (Outperform) both moved to $92. By contrast, Jefferies analyst Tycho Peterson upgraded the stock to Hold from Underperform but set a more cautious $70 target, and J.P. Morgan's Casey Woodring held a Neutral rating at $70. Analysts broadly cite durable revenue growth and an improving profit trajectory, but differ on how richly to value a company that is not yet profitable on a GAAP (generally accepted accounting principles) basis.

Current Market Position and Path Toward the Target

At its most recent close near $78.48, TEM would need to rise about 17% to reach $92 — a substantial move by most measures, though well within the stock's historical volatility. The shares have a 52-week range of roughly $40.77 to $90.53, so a move to $92 would require breaking above the prior 52-week high and into new territory.

The recent catalyst is a stronger-than-expected third quarter. Revenue rose 23% year over year to about $411.5 million, ahead of consensus, while adjusted EPS (earnings per share) of $0.07 beat expectations for a loss. Oncology-testing volumes grew about 32%, and the company raised the lower end of its full-year revenue guidance to $1.6 billion, representing roughly 25% growth.

What Could Support a Move Toward the Target

  • Accelerating testing volumes, including minimal residual disease testing that surged roughly 300% year over year.
  • A data-and-applications segment that grew about 33% year over year, supported by pharmaceutical clients.
  • Expanded partnerships with Bristol Myers Squibb (through 2031), Merck, and Moderna.
  • A $1.5 billion acquisition of Personalis that has cleared regulatory review, strengthening its cancer-detection position.
  • Rising analyst targets following the earnings beat, a sign of improving sentiment.

What Could Prevent the Target From Being Reached

  • The company remains unprofitable on a GAAP basis, with a trailing EPS near negative $1.06 and no meaningful P/E (price-to-earnings) ratio to anchor valuation.
  • A price-to-book ratio near 28 means expectations are already elevated, leaving little room for disappointment.
  • Operating losses have been persistent even as revenue grows, and the Personalis integration carries execution risk.
  • A wide analyst range, with several Hold ratings near $70, signals that some firms see the shares as fully valued at current levels.
  • Macroeconomic sensitivity, rate moves, and sector rotation away from high-multiple growth names could compress the multiple.

Technical Levels and Market Structure

The most relevant technical marker is the 52-week high near $90.53, which also serves as a resistance level. A move to $92 would mean clearing that ceiling and printing a fresh 52-week high, a bullish signal if sustained. The stock's 52-week low near $40.77 and its rise of roughly 90% off that floor show how volatile the name can be. The $100 level, flagged by BTIG, is the next psychological target above the $92 central figure.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though firms do not always state this explicitly and it varies by analyst. Investors should watch quarterly earnings and guidance, oncology-testing and MRD volume trends, the data-and-applications segment, progress integrating Personalis, further analyst revisions, and any changes to pharmaceutical partnerships. Interest-rate decisions and broader healthcare-sector sentiment may also influence the valuation multiple.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like Tempus AI, these signals can help traders spot shifting momentum and monitor positions more efficiently. The tool is designed to complement, not replace, independent research by surfacing trend changes across the market. Explore the AI Daily Buy/Sell Signals to see how AI-driven monitoring can support your own decision-making process.

Final Assessment

Reaching $92 would require Tempus AI to climb roughly 17% and clear its 52-week high, a substantial but not unprecedented move for this stock. The strongest supports are accelerating testing volumes, growing data revenue, and a string of upward analyst revisions after a strong quarter. The principal obstacles are the absence of GAAP profitability, an elevated price-to-book ratio, and a wide range of analyst views — with several firms holding targets near $70. The central $92 figure reflects only the bullish half of the analyst distribution, so investors should weigh the full $67-to-$100 range and monitor earnings, the Personalis integration, and any shift in growth momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

TEM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TEM has been loosely correlated with SDGR. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if TEM jumps, then SDGR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEM
1D Price
Change %
TEM100%
-9.34%
SDGR - TEM
63%
Loosely correlated
-12.95%
TXG - TEM
52%
Loosely correlated
-9.72%
SOPH - TEM
47%
Loosely correlated
-6.74%
GEHC - TEM
40%
Loosely correlated
-1.53%
CERT - TEM
36%
Loosely correlated
-1.22%
More

Groups containing TEM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEM
1D Price
Change %
TEM100%
-9.34%
Services to the Health Industry
industry (41 stocks)
20%
Poorly correlated
-3.31%
Health Services
industry (238 stocks)
6%
Poorly correlated
-2.69%
Can Tempus AI (TEM) Stock Reach $92?